/PRNewswire/ Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced the appointment of.
Neurana Pharmaceuticals to Present at 21st Annual Pain Therapeutics Conference
News provided by
Share this article
Share this article
SAN DIEGO, May 11, 2021 /PRNewswire/ Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that Randall Kaye, Chief Medical Officer, will present at the 21
st Annual Pain Therapeutics Conference. The conference takes place virtually May 10-11
th. Presentations will be available for registered attendees via the conference website.
About Neurana Pharmaceuticals, Inc.
Neurana Pharmaceuticals, Inc. is a privately held, clinical-stage, biotechnology company focused on the treatment of neuromuscular conditions, including acute, painful muscle spasms of the back. The company was founded in 2013 and is based in San Diego. Neurana s lead development compound is tolperisone, a novel, non-opioid, non-drowsy, non-cognitive impairing treatment, which the company is developing for the l
Gina Biachinin s Mighty Networks scores $50M to help creators and brands grow communities bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
(0)
Novel mucoadhesive patch adheres to wet tissue surfaces and enables targeted, localized delivery of therapeutic to lesions inside the mouth AFYX Therapeutics ( AFYX ), a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced that a study of the Rivelin Clobetasol patch ( Rivelin-CLO ), a novel adhesive patch technology designed to deliver a therapeutic agent to wet tissue surfaces, was featured in the March issue of
The European Journal of Oral Sciences. This is the first study to show the successful transmucosal delivery of a corticosteroid using electrospun patch technology and confirmed that the drug delivered retained its anti-inflammatory activity.
Ascendis Pharma A/S Announces Equity Investment in VISEN Pharmaceuticals
– Advances Vision 3×3 to extend global clinical and commercial reach –
COPENHAGEN, Denmark, Jan. 08, 2021 (GLOBE NEWSWIRE) Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced an equity investment of $12.5 million in VISEN Pharmaceuticals (VISEN) as part of VISEN’s $150 million Series B financing.
“Our relationship with VISEN is a key element of our Vision 3×3 strategy to extend the global reach of our TransCon endocrinology rare disease product candidates and improve patients’ lives around the world,” said Jan Mikkelsen, President and CEO at Ascendis Pharma. “Since VISEN’s inception in 2018, the company has made significant progress on its clinical activities in Greater China, which we believe will enable us to get our products to patients worldw